The 10-15 year figure was for a traditional 'non-cannabinoid' drug pathway - basically a new chemical/ingredient. Cannabinoids aren't new, there is a lot known about them so that figure isn't relevant to Auscann.
The hard shell is definitely their first product and is therefore enormously important, so the focus is rightly there.
But I'm sure over the next few years they'll be looking at other innovations - that's the whole reason for the new labs.
I thought he was pretty clear on where they saw the value in the hard shell. IMO they are unquestionably valuable and will be more so after a (hopefully) successful phase 1 trial.
- Forums
- ASX - By Stock
- AC8
- Ann: AusCann Investor Webinar Recording
Ann: AusCann Investor Webinar Recording, page-6
-
-
- There are more pages in this discussion • 86 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AC8 (ASX) to my watchlist
|
|||||
Last
4.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.62M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AC8 (ASX) Chart |
Day chart unavailable